# Adempas - (0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral)

| | | | |
|---|---|---|---|
| **Generic Name** | Riociguat | **Innovator** | Bayer |
| **Dosage** | 0.5, 1, 1.5, 2, 2.5 mg; Tablet, Oral | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | More Than 5 | **Tentative Approvals** | Less Than 5 |
| **Final Approvals** | Less Than 5 | **Generic Launches** | None |
| **Indication** | Indicated for Treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.